AstraZeneca-DRL patent case: Fate of Rs 2.35 bn drug to be decided today

AstraZeneca has dragged Dr Reddy's Laboratories to the court to protect its blood clot inhibitor drug Brilinta from generic competition

British drug maker AstraZeneca's lawsuit against Dr Reddy's Laboratories to block it from launching generic versions of its medicine for heart ailments will come up for hearing in the Delhi High Court on Tuesday.

AstraZeneca has dragged Dr Reddy's Laboratories to the court to protect its Rs 2.35 billion blood clot inhibitor drug Brilinta from generic competition.

AstraZeneca launched Brilinta (molecule name Ticagrelor) in the domestic market in 2012 and is now the largest selling drug in the segment.

Globally, the drug has raked in over one billion dollar in sales for the British drugmaker which is seeking to thwart